Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Ketamine for Laceration Repair in Children
NCT03053947Phase 2Completed
- Start
- Feb 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in laceration. Primary endpoints: Optimal dose of intranasal ketamine for adequate procedural sedation at 18 months and Evaluation of the dose determined in DosINK 1 at 18 months. Started Feb 2017; status: completed.
02
Drugs
ketamine
03
Conditions
laceration
Beyond the preview
Go deeper on NCT03053947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053947.